

## INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

<b>OMB APPROVAL</b>	
OMB Number:	3235-0104
Estimated average burden hours per response:	0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934  
or Section 30(h) of the Investment Company Act of 1940

<b>1. Name and Address of Reporting Person*</b> <u>Palling David</u>  (Last) (First) (Middle) <u>C/O AMICUS THERAPEUTICS, INC.</u> <u>6 CEDAR BROOK DRIVE</u>  (Street) <u>CRANBURY NJ 08512</u>  (City) (State) (Zip)	<b>2. Date of Event Requiring Statement (Month/Day/Year)</b> <u>05/30/2007</u>	<b>3. Issuer Name and Ticker or Trading Symbol</b> <u>AMICUS THERAPEUTICS INC [ FOLD ]</u>  <table style="width: 100%; border: none;"> <tr> <td colspan="2"><b>4. Relationship of Reporting Person(s) to Issuer (Check all applicable)</b></td> <td style="width: 20%;"><b>5. If Amendment, Date of Original Filed (Month/Day/Year)</b></td> </tr> <tr> <td style="width: 50%; vertical-align: top;"> <input checked="" type="checkbox"/> Director  <input checked="" type="checkbox"/> Officer (give title below)  <u>Senior VP, Drug Development</u> </td> <td style="width: 50%; vertical-align: top;"> <input type="checkbox"/> 10% Owner  <input type="checkbox"/> Other (specify below)                 </td> <td style="vertical-align: top;"> <input type="checkbox"/>  <input checked="" type="checkbox"/> </td> </tr> </table>	<b>4. Relationship of Reporting Person(s) to Issuer (Check all applicable)</b>		<b>5. If Amendment, Date of Original Filed (Month/Day/Year)</b>	<input checked="" type="checkbox"/> Director <input checked="" type="checkbox"/> Officer (give title below) <u>Senior VP, Drug Development</u>	<input type="checkbox"/> 10% Owner <input type="checkbox"/> Other (specify below)	<input type="checkbox"/> <input checked="" type="checkbox"/>
<b>4. Relationship of Reporting Person(s) to Issuer (Check all applicable)</b>		<b>5. If Amendment, Date of Original Filed (Month/Day/Year)</b>						
<input checked="" type="checkbox"/> Director <input checked="" type="checkbox"/> Officer (give title below) <u>Senior VP, Drug Development</u>	<input type="checkbox"/> 10% Owner <input type="checkbox"/> Other (specify below)	<input type="checkbox"/> <input checked="" type="checkbox"/>						
<b>6. Individual or Joint/Group Filing (Check Applicable Line)</b> <input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person								

### Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	48,866	D	
Common Stock	6,666 <sup>(1)</sup>	I	By David Palling Irrevocable Trust

### Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date				
Employee Stock Option (right to buy)	(2)	12/15/2014	Common Stock	24,924	0.638	D
Employee Stock Option (right to buy)	(3)	10/20/2015	Common Stock	30,000	5.33	D
Employee Stock Option (right to buy)	(4)	02/28/2016	Common Stock	2,667	5.33	D
Employee Stock Option (right to buy)	(5)	04/25/2017	Common Stock	16,667	13.43	D

#### Explanation of Responses:

1. These shares are held by the David Palling Irrevocable Trust. Mr. Palling disclaims beneficial ownership of the shares held by the David Palling Irrevocable Trust except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of the shares for the purposes of section 16 or for any other purpose.
2. These options vest and become exercisable in a series of installments. The first installment, which consisted of 25% of the total aggregate number of options granted, vested on July 1, 2005. The remaining options vest and become exercisable in a series of thirty-five successive equal monthly installments of 1,010 shares, beginning on August 1, 2005, with a final installment of 991 shares vesting on July 1, 2008.
3. These options vest and become exercisable in a series of installments. The first installment, which consisted of 25% of the total aggregate number of options granted, vested on October 20, 2006. The remaining options vest and become exercisable in a series of thirty-five successive equal monthly installments of 626 shares, beginning on November 1, 2006, with a final installment of 590 shares vesting on October 1, 2009.
4. These options vest and become exercisable in a series of installments. The first installment, which consisted of 25% of the total aggregate number of options granted, vested on January 2, 2007. The remaining options vest and become exercisable in a series of thirty-five successive equal monthly installments of 56 shares, beginning on February 1, 2007 with a final installment of 40 shares vesting on January 1, 2010.
5. These options vest and become exercisable in a series of installments. The first installment, which consists of 25% of the total aggregate number of options granted, will vest on April 25, 2008. The remaining options vest and become exercisable in a series of thirty-five successive equal monthly installments of 348 shares, beginning on May 1, 2008, with a final installment of 320 shares vesting on April 1, 2011.

/s/ Douglas A. Branch,  
Attorney-in-fact

05/30/2007

\*\* Signature of Reporting Person      Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

AMICUS THERAPEUTICS, INC.

POWER OF ATTORNEY

Know all by these presents, that the undersigned hereby constitutes and appoints John F. Crowley, John M. McAdam, Douglas A. Branch and James E. Dentzer, each individually, as the undersigned's true and lawful attorneys-in-fact to:

(1) execute for and on behalf of the undersigned, in the undersigned's capacity as an officer and/or director of Amicus Therapeutics, Inc. (the "Company"), Forms 3, 4, and 5 in accordance with Section 16(a) of the Securities Exchange Act of 1934 and the rules thereunder;

(2) do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such Form 3, 4, or 5 and timely file such form with the United States Securities and Exchange Commission and any stock exchange or similar authority; and

(3) take any other action of any type whatsoever in connection with the foregoing which, in the opinion of any such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by any such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact's discretion.

The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorneys-in-fact, or such attorneys-in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that neither of the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, is assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with Section 16 of the Securities Exchange Act of 1934.

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4, and 5 with respect to the undersigned's holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to each of the foregoing attorneys-in-fact.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 24th day of May, 2007.

/s/ David Palling  
-----  
Name: David Palling